Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers.
Although constituting only 1% of all human malignancies, sarcomas represent the second …

The macrophage is a key cell in the pro-and anti-inflammatory response including that of the
inflammatory microenvironment of malignant tumors. Much current drug development in …

Early trials for immune checkpoint inhibitors in sarcomas have delivered mixed results, and
efforts to improve outcomes now look to combinatorial strategies with novel …

Immunotherapy by immune checkpoint inhibitors has become a standard treatment strategy
for many types of solid tumors. However, the majority of patients with cancer will not …

Sarcomas are uncommon malignancies of mesenchymal origin that can arise throughout the
human lifespan, at any part of the body. Surgery remains the optimal treatment modality …

Paediatric rhabdomyosarcoma (RMS) is a soft tissue malignancy of mesenchymal origin that
is thought to arise as a consequence of derailed myogenic differentiation. Despite intensive …

Overwhelming evidence has shown the significant role of the tumor microenvironment (TME)
in governing the triple-negative breast cancer (TNBC) progression. Digital pathology can …

Introduction Metastatic rhabdomyosarcoma (RMS) is a challenging tumor entity that evades
conventional treatments and endogenous antitumor immune responses, highlighting the …

Rhabdomyosarcoma (RMS) is the most common soft tissue cancer in children. Treatment
outcomes, particularly for relapsed/refractory or metastatic disease, have not improved in …

Simple Summary Soft tissue sarcoma is a rare mesenchymal malignancy. Despite the
advancements in the fields of radiology, pathology and surgery, these tumors often recur …